Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure
Status:
Unknown status
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Liver failure (LF) is a dramatic clinical syndrome with massive necrosis of liver cells. and
liver transplantation is the only available therapeutic option for patients suffering with
this condition. However, lack of donors, surgical complications, rejection, and high cost are
serious problems. Previous study showed that bone marrow derived mesenchymal stem cells
(BM-MSCs) replace hepatocytes in injured liver, and effectively rescue experimental liver
failure and contribute to liver regeneration. In this study, the patients with LF will
undergo administration of human umbilical cord mesenchymal stem cells (UC-MSCs) via
peripheral vein transfusion to evaluate the safty and efficacy of UC-MSCs treatment for these
patients.